Novel synergistic ATR inhibitor combinations for ovarian cancer therapy

The Department of the Army Medical Command awarded a $1,039,740 project grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to support research titled "NOVEL SYNERGISTIC ATR INHIBITOR COMBINATIONS FOR OVARIAN CANCER THERAPY." The period of performance is from August 1, 2021 to July 31, 2025.

This project grant was awarded under the Military Medical Research and Development program (CFDA 12.420). This program supports basic, applied, and advanced biomedical research with the goals of transforming military and public health care through innovative research and investigating medical solutions for battlefield medicine. Specifically, this award will support Dfci's research into novel combinations of drugs to inhibit ATR, a protein involved in DNA damage response, as a potential therapy for ovarian cancer. Results from this research could lead to new treatment approaches for both service members and civilians suffering from this type of cancer.